Trial
NCT02120417
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Incyte Corporation
Collaborators
—
Condition
Breast Cancer
Intervention
Ruxolitinib
Why stopped
The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-13